LAUNCH SALE ENDS OCTOBER 1, 2025
FREE SHIPPING ON USA SUPPLEMENT ORDERS OVER $75USD
FREE SHIPPING ON INTL SUPPLEMENT ORDERS OVER $150USD
FREE SHIPPING ON USA SUPPLEMENT ORDERS OVER $75USD
FREE SHIPPING ON INTL SUPPLEMENT ORDERS OVER $150USD
+1 518-558-4528
+1 833-933-2106
+1 833-933-2106
support@over40alphacoffeeshop.com
LAUNCH SALE ENDS OCTOBER 1, 2025
FREE SHIPPING ON USA SUPPLEMENT ORDERS OVER $75USD
FREE SHIPPING ON INTL SUPPLEMENT ORDERS OVER $150USD
FREE SHIPPING ON USA SUPPLEMENT ORDERS OVER $75USD
FREE SHIPPING ON INTL SUPPLEMENT ORDERS OVER $150USD
+1 518-558-4528
+1 833-933-2106
+1 833-933-2106
support@over40alphacoffeeshop.com
Tesamorelin is a growth hormone-releasing factor analog that stimulates your pituitary gland to release more of your own growth hormone. Its FDA-approved use is reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss drug, bodybuilding peptide, or anti-aging treatment, although it is widely discussed in those circles because of its effects on visceral fat and GH/IGF-1 signaling.
If you have been following Peptide Class, tesamorelin is especially interesting because it sits in a very different category from compounds such as tirzepatide, retatrutide, BPC-157 or MOTS-c.
Tirzepatide and retatrutide primarily work through metabolic hormone receptors that influence appetite, glucose regulation and energy balance.
Tesamorelin works through your growth hormone system.
And that makes it particularly interesting when we start talking about:
And potentially some of the changes that become increasingly relevant as men move through their 40s, 50s and 60s.
But there is one HUGE distinction I want you to understand from the beginning.
Tesamorelin is actually an FDA-approved medication.
However, its approved use is very specific.
Let’s break it all down.
This article is for educational purposes only and is not medical advice, diagnosis, treatment, prescribing guidance or a recommendation to use tesamorelin. FDA-approved tesamorelin has specific indications, contraindications, warnings, formulation-specific dosing instructions and monitoring requirements. Research compounds sold online should not automatically be assumed to be equivalent to an FDA-approved pharmaceutical product. Always discuss tesamorelin, growth hormone-related therapies and changes in body composition with a qualified healthcare professional who understands your medical history, medications and laboratory results.
Tesamorelin is a synthetic version of a hormone signal your body already uses.
That signal is called:
Sometimes you will also see it called growth hormone-releasing factor, or GHRF.
Here is the simplest way to understand what tesamorelin does.
Your brain contains a structure called the hypothalamus.
The hypothalamus sends signals to your pituitary gland.
One of those signals tells the pituitary:
“Release growth hormone.”
Tesamorelin mimics that signal.
So rather than injecting growth hormone directly into the body, tesamorelin essentially tells your pituitary gland:
“Produce and release more of your OWN growth hormone.”
That distinction is important.
Tesamorelin is not growth hormone itself.
It stimulates your body’s growth hormone axis. The FDA describes it as a growth hormone-releasing factor analog, and current EGRIFTA WR labeling states that it induces endogenous GH release and increases IGF-1.
Let’s make this 8th-grade simple.
Imagine your pituitary gland is a factory that produces growth hormone.
Tesamorelin does not deliver finished growth hormone to that factory.
Instead, it rings the factory bell.
That signal tells the pituitary:
“Release some growth hormone.”
The growth hormone then travels through your body and stimulates several tissues, including your liver.
Your liver responds partly by producing another important hormone called:
That growth hormone/IGF-1 signaling affects multiple biological processes, including fat metabolism, body composition and tissue growth.
And one of the most interesting findings with tesamorelin is its effect on a very specific type of fat:
VISCERAL FAT.
Visceral fat is not the same thing as the soft fat you can pinch under your skin.
That pinchable fat is mainly subcutaneous fat.
Visceral fat sits deeper inside your abdomen around your organs.
And for men over 40, this matters because excessive visceral fat is strongly associated with metabolic problems including:
And other cardiometabolic problems.
So when someone says:
“I want to lose belly fat.”
There can actually be two different types of fat involved.
Tesamorelin became medically important because research showed it could selectively reduce visceral adipose tissue in people with HIV-associated abdominal fat accumulation.
This is where I want to be incredibly clear.
FDA-approved tesamorelin, marketed as EGRIFTA, is indicated for:
Reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Current FDA labeling specifically says that EGRIFTA WR is used to reduce excess abdominal fat in HIV-infected adults with lipodystrophy.
But the same FDA label also states something extremely important:
Tesamorelin is NOT indicated for weight-loss management.
The label describes the medication as essentially weight neutral.
That may sound confusing.
How can something reduce visceral fat but not be a weight-loss medication?
Because:
Losing visceral fat is not necessarily the same thing as losing a large amount of total body weight.
That distinction is critical.
Now we get to the good stuff.
In a randomized controlled trial involving adults with HIV and central fat accumulation, tesamorelin reduced visceral adipose tissue by approximately 10.9% over six months, compared with almost no meaningful reduction in the placebo group. Participants who continued treatment for 12 months reached an approximately 18% reduction in visceral fat.
An earlier large study involving more than 400 participants also found a significant reduction in visceral adipose tissue along with improvements in triglycerides and the total cholesterol-to-HDL ratio.
Those are real human clinical data.
And they are one of the reasons tesamorelin has become such a major conversation in peptide and body-composition communities.
But again:
Those studies involved people with HIV-associated abdominal fat accumulation.
They were not trials of otherwise healthy 50-year-old men trying to get six-pack abs.
That matters.
This is another interesting part of the research.
Tesamorelin appears to be relatively selective for visceral fat.
In one randomized study, visceral adipose tissue declined, while researchers found no significant change in limb fat or abdominal subcutaneous fat.
That means tesamorelin should not be thought of as:
“A peptide that simply burns every type of body fat.”
Its clinical effects appear to be more specific.
And that specificity is part of what makes it interesting.
This may be one of the most fascinating parts of the tesamorelin story.
Researchers have also studied tesamorelin in people with HIV who had excess liver fat.
A randomized clinical trial found that six months of tesamorelin significantly reduced both visceral adipose tissue and liver fat compared with placebo.
Then researchers took the question even further.
A later randomized, double-blind trial studied people with HIV and fatty liver disease for 12 months.
Tesamorelin reduced hepatic fat fraction by an absolute 4.1 percentage points compared with placebo, representing an approximately 37% relative reduction from baseline.
Again, that’s very interesting.
But it does NOT mean tesamorelin is FDA-approved as a general fatty-liver treatment.
The evidence was specifically generated in people with HIV.
Potential Benefits of Tesamorelin
When we look at what the human research actually supports, the most established benefit is:
Reduction of visceral abdominal fat in adults with HIV-associated lipodystrophy.
Research has also shown potential improvements in several related measures, including:
And increased IGF-1, which reflects activation of the GH axis.
But I would NOT make claims such as:
“Tesamorelin replaces growth hormone.”
Those statements go beyond the evidence.
Tesamorelin and Growth Hormone After 40
This is probably where men over 40 become really interested.
Growth hormone secretion changes as we age.
That has led to enormous interest in compounds such as:
Tesamorelin is especially interesting because unlike many “research peptides” marketed online, tesamorelin has been studied extensively enough to become an approved medication for one particular medical use.
However, that does NOT make tesamorelin an approved “anti-aging peptide.”
Those are completely different claims.
This is going to be a great future comparison article.
Both tesamorelin and CJC-1295 are associated with growth hormone-releasing signaling.
But tesamorelin has a much more established pharmaceutical evidence base and an FDA-approved medical indication.
CJC-1295 remains investigational.
So while both are discussed as GHRH-related compounds, they should not simply be treated as interchangeable versions of the same thing.
Ipamorelin works differently.
Ipamorelin is a growth hormone secretagogue that acts primarily through the ghrelin receptor.
Tesamorelin mimics GHRH signaling.
Think:
That is why you’ll frequently see GHRH-type compounds paired with ghrelin-receptor secretagogues in peptide communities.
But popularity of a combination does not automatically mean that the combination has been proven superior in controlled human trials.
This is probably one of the most important AEO questions in the article.
No—not in the way tirzepatide or semaglutide are weight-loss medications.
FDA labeling specifically states that tesamorelin is not indicated for weight-loss management and has a weight-neutral effect.
Its clinically established effect is much more targeted:
Reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
That is a very different claim.
For FDA-approved treatment, the population is clear:
Adults with HIV-associated lipodystrophy and excess abdominal fat.
Outside that population, the evidence becomes far less established.
That means I would NOT say:
“Every man over 40 with belly fat is an ideal tesamorelin candidate.”
We do not have the clinical evidence to make that claim.
If someone is interested in tesamorelin outside its approved indication, that becomes an off-label medical conversation that should involve a qualified healthcare professional.
Current EGRIFTA WR labeling lists several important contraindications.
Tesamorelin should not be used in people with disruption of the hypothalamic-pituitary axis caused by conditions such as pituitary surgery, hypopituitarism, pituitary tumors, head irradiation or certain head injuries.
It is also contraindicated in people with active malignancy, known hypersensitivity to tesamorelin or its ingredients, and during pregnancy.
The active-malignancy warning matters because tesamorelin stimulates growth hormone and increases IGF-1, both of which are growth-related signaling pathways.
Potential Side Effects of Tesamorelin
Tesamorelin is a real prescription drug.
That means it comes with real potential adverse effects.
Current FDA labeling lists commonly reported adverse reactions including:
and
Muscle pain.
The label also warns about:
and considerations around malignancy.
This is exactly why I don’t want guys thinking:
“It’s just a peptide, so what’s the big deal?”
Peptide does not mean harmless.
This deserves special attention.
Growth hormone can affect insulin sensitivity and glucose metabolism.
The current FDA label warns that glucose intolerance or diabetes may develop during tesamorelin treatment and recommends evaluating glucose before and during therapy.
Interestingly, some clinical studies did not show major long-term deterioration in fasting glucose among the studied populations, although short-term increases occurred in some research.
So the right takeaway isn’t:
“Tesamorelin destroys your blood sugar.”
or
“Tesamorelin has no effect on glucose.”
The more accurate statement is:
Glucose metabolism should be monitored.
Tesamorelin raises IGF-1.
That is expected because it activates growth hormone signaling.
But more isn’t automatically better.
The FDA recommends monitoring IGF-1 levels during EGRIFTA treatment and considering discontinuation in patients with persistent elevations.
That’s particularly important for men over 40 because online peptide culture sometimes talks about IGF-1 as though the goal should be:
“Get it as high as possible.”
That is NOT smart medicine.
The goal is appropriate physiology—not maximum numbers.
This section is particularly important because there are currently multiple EGRIFTA formulations, and they are not interchangeable.
The newer EGRIFTA WR formulation contains 11.6 mg per vial. The FDA-approved dose is 1.28 mg subcutaneously once daily. The vial is reconstituted with the specific bacteriostatic water supplied with the product, and one prepared vial provides seven daily doses.
The FDA specifically warns that EGRIFTA WR and EGRIFTA SV have different strengths, doses, reconstitution procedures and storage requirements and are not substitutable.
That is a perfect example of why you cannot simply Google:
“How many units of tesamorelin?”
and use somebody else’s answer.
You need to know:
Again, this depends on the specific formulation.
For current FDA-approved EGRIFTA WR, one reconstituted vial provides seven days of treatment and unused solution should be discarded seven days after mixing. Interestingly, the reconstituted WR formulation is stored at controlled room temperature rather than automatically refrigerated.
That is another important Peptide Class lesson:
“All reconstituted peptides go in the fridge” is NOT a universal rule.
Product-specific instructions always win.
You’ll commonly see tesamorelin discussed alongside:
Ipamorelin.
CJC-1295.
MOTS-c.
and sometimes metabolic peptides.
But again, a popular stack isn’t automatically a clinically validated combination.
For the FDA-approved tesamorelin indication, the evidence is for tesamorelin used according to its approved treatment protocol—not a cocktail of research peptides.
So I would describe peptide stacks involving tesamorelin as:
Experimental unless there is specific controlled human evidence supporting the combination.
Yes. Tesamorelin is FDA approved under the EGRIFTA brand for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Yes, in its studied HIV-associated lipodystrophy population. Human trials have demonstrated meaningful reductions in visceral adipose tissue.
Does tesamorelin cause overall weight loss?
It is not FDA-approved for weight-loss management, and the FDA describes it as having a weight-neutral effect.
Is tesamorelin growth hormone?
No. Tesamorelin stimulates your pituitary gland to release your own endogenous growth hormone.
Does tesamorelin raise IGF-1?
Yes. Increasing IGF-1 is an expected downstream effect of increased growth hormone signaling, which is why FDA labeling recommends monitoring IGF-1 during treatment.
Does tesamorelin help liver fat?
Human research in people with HIV and fatty liver disease has shown significant reductions in liver fat. It is not currently FDA-approved as a general treatment for fatty liver disease.
Is tesamorelin good for belly fat after 40?
Tesamorelin has strong evidence for visceral-fat reduction in HIV-associated lipodystrophy. Evidence is insufficient to claim that it is an established treatment for ordinary age-related abdominal fat in otherwise healthy men.
Is tesamorelin the same as CJC-1295?
No. Both are associated with GHRH signaling, but they are different molecules with very different levels of clinical evidence and regulatory status.
Is tesamorelin the same as ipamorelin?
No. Tesamorelin acts through the GHRH pathway, while ipamorelin is a growth hormone secretagogue acting largely through the ghrelin receptor.
Does tesamorelin build muscle?
Tesamorelin increases growth hormone and IGF-1 signaling, but its FDA-approved use is visceral-fat reduction in HIV-associated lipodystrophy—not muscle building.
Is tesamorelin safe?
Tesamorelin has undergone controlled human clinical trials and has an FDA-approved indication, but it still has contraindications, warnings and potential adverse effects. It should be used under appropriate medical supervision.
Tesamorelin is one of the most interesting peptides we’re going to cover in Peptide Class because it sits in the middle of two worlds.
On one side, you’ve got peptide culture talking about:
On the other side, we actually have a real FDA-approved peptide medication with substantial human clinical research.
That makes tesamorelin very different from many compounds sold exclusively as research peptides.
The science tells us that tesamorelin:
Stimulates endogenous growth hormone release.
Raises IGF-1.
Can significantly reduce visceral abdominal fat in people with HIV-associated lipodystrophy.
Has demonstrated effects on liver fat in certain HIV populations.
And also carries real considerations around:
and other side effects.
So where do I put tesamorelin for men over 40?
VERY INTERESTING.
But I would not call it a proven general belly-fat solution for every man.
And I definitely wouldn’t call it a magic anti-aging peptide.
For men over 40, 50 and 60, visceral fat absolutely matters.
Growth hormone signaling matters.
Metabolic health matters.
But the foundation is still:
Tesamorelin may be a legitimate medical tool for certain people.
But as always:
The peptide is a tool.
It isn’t the toolbox.
That’s exactly why we’re doing Peptide Class.
Understand the biology.
Understand the research.
Understand the risks.
And then separate what is proven, promising, and experimental.
Get It Done.
Funk
